IBM's new partnership with research firm Boehringer Ingelheim to use fundameal artificial ielligence models to help discover new therapeutic aibodies. Aibodies are the domina weapon in the fight against a wide range of serious diseases and have far fewer side effects than more traditional treatmes. In the traditional methods of aibody production, researchers have to go through a complicated and long process, now with the help of IBM artificial ielligence, this process has become shorter and more efficie.
According to a report on IBM's website, the company was to help produce life-saving treatmes by developing a fundameal artificial ielligence model for aibody research. One of the most importa challenges that hinders the developme of new aibody therapies is the laboratory nature of aibody research. Successful developme of a new aibody treatme requires corolled iteration, meaning that new treatmes cannot be produced quickly.
Aibody production with the help of IBM artificial ielligence
Aibodies in the treatme of many diseases including Cancer, autoimmune and infectious diseases They play an esseial role. Despite major advances in technology, the discovery and developme of therapeutic aibodies that cover various ages is a very complex and time-consuming process.
“Fundameal models can be used for problems and data that are outside the domain of language,” said Alessandro Corioni, director of research at IBM in Zurich, at the launch of the IBM Research Lab. did.”
IBM and Boehringer Ingelheim hope to develop new aibodies using artificial ielligence Production of previously unexplored molecules And Removal of ineffective molecules, allowing researchers to focus on promising candidates. In this way, the efficiency and speed of aibody discovery increases to a great exte.
This artificial ielligence actually quickly examines the combinations with the help of data and ideifies those that have fruitful results. With the help of this artificial ielligence, researchers can focus on more valuable things.
